Ester derivatives of annulated tetrahydroazocines: A new class of selective acetylcholinesterase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 21, 2006, Pages 7205-7212

  Carotti, Andrea ^a   de Candia, Modesto ^a   Catto, Marco ^a   Borisova, Tatiana N ^b   Varlamov, Alexey V ^b   Méndez Álvarez, Estefanía ^c   Soto Otero, Ramón ^c   Voskressensky, Leonid G ^b   Altomare, Cosimo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Annulated azocines; Structure activity relationships

Indexed keywords

ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING); AZOCINE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIMETHYL 3 ETHYL 6 BENZYL 2,3,6,7 TETRAHYDRO 1H AZOCINO[5,4 B]INDOLE 4,5 DICARBOXYLATE; ETHYL 3 ETHYL 2,3,4,5,6,11 HEXAHYDRO 1H AZOCINO[4,5 B]INDOLE 5 CARBOXYLATE; ETHYL 3 ETHYL 6 BENZYL 2,3,6,7 TETRAHYDRO 1H AZOCINO[5,4 B]INDOLE 5 CARBOXYLATE; ETHYL 7 BENZYL 2 (2,2,2 TRIFLUOROACETYL) 4,7,8,9 TETRAHYDRO 1H PYRROLO[2,3 D]AZOCINE 5 CARBOXYLATE; OCTANOL; UNCLASSIFIED DRUG; WATER;

ARTICLE; CHOLINESTERASE INHIBITION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; IC 50; LIPOPHILICITY; PARTITION COEFFICIENT; SIMULATION; STRUCTURE ACTIVITY RELATION; TORPEDO CALIFORNICA; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; ANIMALS; AZOCINES; CATTLE; CHOLINESTERASE INHIBITORS; ERYTHROCYTES; ESTERS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

TORPEDO CALIFORNICA;

EID: 33748755627     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.055     Document Type: Article

References (37)

1. Bertha C.M., Ellis M., Filippen-Anderson J.L., Porreca F., Rothman R.B., Davis P., Xu H., Becketts K., and Rice K.C. J. Med. Chem. 38 (1996) 2081
2. Alvarez, M.; Joule, A. Alkaloids; Chemistry and Biology; Academic Press: New York, 2001; Vol. 57, pp 235-272.
3. Bennasar M.-L., Zulaica E., Ramirez A., and Bosch J. Tetrahedron 55 (1999) 3117
4. Alazard J.-P., Millet-Paillusson C., Guenard D., and Thal C. Bull. Soc. Chim. Fr. 133 (1996) 251
5. Gil L., Gil R.P.d.F., dos Santos D.C., and Marazano C. Tetrahedron Lett. 41 (2000) 6067
6. Varlamov A.V., Borisova T.N., Voskressensky L.G., Kulikova L.N., Soklakova T.A., Chernyshev A.I., and Alexandrov G.G. Tetrahedron Lett. 43 (2002) 6767
7. Varlamov A.V., Borisova T.N., and Voskressensky L.G. Synthesis 2 (2002) 155
8. Voskressensky L.G., Borisova T.N., Kulikova L.N., Varlamov A.V., Catto M., Altomare C., and Carotti A. Eur. J. Org. Chem. (2004) 3128
9. Carreiras M.C., and Marco J.L. Curr. Pharm. Des. 10 (2004) 3167
10. O'Neill M.F. Drug Discovery Today 10 (2005) 1333
11. Davis K.L., and Powchik P. Lancet 345 (1995) 625
12. Prous J., Rabasseda X., and Castaner J. Drugs Future 19 (1996) 656
13. Sugimoto H., Iimura Y., Yamanishi Y., and Yamatsu K. J. Med. Chem. 38 (1995) 4821
14. Michaelis M.L. J. Pharmacol. Exp. Ther. 304 (2003) 897
15. Grossberg G.T. Int. Psychogeriatr. 14 Suppl. 1 (2002) 27
16. Darvesh S., Hopkins D.A., and Geula C. Nat. Rev. Neurosci. 4 (2003) 131
17. Fawcett J.R., Bordayo E.Z., Jackson K., Liu H., Peterson J., Svitak A., and Frey II W.H. Brain Res. 950 (2002) 10
18. Weinstock M., Poltyrev T., Bejar C., and Youdim M.H. Psychopharmacology 160 (2002) 318
19. Voskressensky L.G., Borisova T.N., Soklakova T.A., Kulikova L.N., Borisov R.S., and Varlamov A.V. Lett. Org. Chem. 2 (2005) 18
20. Voskressensky L.G., Borisova T.N., Kostenev I.S., Kulikova L.N., and Varlamov A.V. Tetrahedron Lett. 47 (2006) 999
21. Ellman G.L., Courtney K.D., Andres Jr. V., and Feather-Stone R.M. Biochem. Pharmacol. 7 (1961) 88
22. Cygler M., Schrag J.D., Sussman J.L., Harel M., Silman I., Gentry M.K., and Doctor B.P. Protein Sci. 2 (1993) 366
23. Kovarik Z., Bosak A., Sinko G., and Latas T. Croat. Chem. Acta 76 (2003) 63
24. Barreiro E.J., Camara C.A., Verli H., Brazil-Más L., Castro N.G., Cintra W.M., Aracava Y., Rodrigues C.R., and Fraga C.A.M. J. Med. Chem. 46 (2003) 1144
25. Gnerre C., Catto M., Leonetti F., Weber P., Carrupt P.-A., Altomare C., Carotti A., and Testa B. J. Med. Chem. 43 (2000) 4747
26. Bruhlmann C., Ooms F., Carrupt P.-A., Testa B., Catto M., Leonetti F., Altomare C., and Carotti A. J. Med. Chem. 44 (2001) 3195
27. Carotti A., Altomare C., Catto M., Gnerre C., Summo L., De Marco A., Rose S., Jenner P., and Testa B. Chem. Biodiv. 3 (2006) 134
28. McMartin C., and Bohacek R.S. J. Comput. Aided Mol. Des. 11 (1997) 333
29. Greenblatt H.M., Kryger G., Lewis T., Silman I., and Sussman J.L. FEBS Lett. 463 (1999) 321
30. In order to generate suitable docking poses of the ligand structures 11 and 15, with a good sampling of the conformational space, 500 runs of Monte Carlo search followed by conjugate gradient minimization were performed, resulting in 20 low-energy docking solutions. The lowest-energy docked structures (i.e., complexes within 1 kcal/mol range from the minimum-energy MCDOCK solution) were compared to the X-ray structure of galanthamine.
31. Avdeef A. Quant. Struct.-Act. Relat. 11 (1992) 510
32. Avdeef A. J. Pharm. Sci. 82 (1993) 183
33. Avdeef A., Box K.J., Comer J.E.A., Hibbert C., and Tam K.Y. Pharm. Res. 15 (1998) 209
34. Takács-Novák K., Box K.J., and Avdeev A. Int. J. Pharm. 151 (1997) 235
35. Kraemer S.D., Gautier J.-C., and Saudemon P. Pharm. Res. 15 (1998) 1310
36. Méndez-Álvarez E., Soto-Otero R., Sánchez-Sellero I., and López-Rivadulla Lamas M. Life Sci. 60 (1997) 1719
37. Soto-Otero R., Méndez-Álvarez E., Hermida-Ameijeiras A., Sánchez-Sellero I., Cruz-Landeira A., and López-Rivadulla Lamas M. Life Sci. 69 (2001) 879